Hematology analyzers are used to count the number of white blood cells, red blood cells, and platelets in blood. Clinical testing laboratories, hospitals, and research institutions are some of the users of hematology analyzers and reagents. A recent report published by Persistence Market Research provides the trends, growth factors and analysis of the global hematology analyzer and reagent market for the year 2015 to 2021.
Along with assisting the diagnosis of various diseases and conditions such as infections, anemia, viruses, diabetes, genetic problems and cancer, hematology analyzers also regulate plasma drug level for both therapeutic and illicit drugs. Based on the type of automation, fully-automated and semi-automated models of analyzers are available.
As per the report, key factors that drive the growth of the market are:
- Increasing adoption of automated hematology instruments
- Rising technological advancements
- Integration of basic flow-cytometry techniques
- Rising demand for high-throughput hematology analyzers
- Development of high-sensitivity point-of-care (POC) hematology testing
However, factors that restrain the growth of the market include high cost of hematology analyzers, intense competition among existing players, and stringent, time-consuming regulatory policies for hematology instruments.
One of the recent trends in the market is the increasing instances of partnership among hematology instruments and consumables manufacturers. The report predicts that advanced technologies such as usage of microfluidics technology in hematology analyzers, introduction of digital imaging system in hematology laboratories and increasing focus toward emerging markets such as India and China could open up opportunities for new players in the market.
Leading manufacturers in the market are Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Mindray Medical International Limited, Siemens Healthcare, HORIBA, Ltd. and NIHON KOHDEN CORPORATION.
Due to the region’s high disposable income and increasing adoption of automated hematology instruments by diagnostics laboratories, North America is currently dominating the hematology analyzer and reagent market, followed by Europe. During the forecast period, Asia is expected to be the fastest growing market due to the developing healthcare infrastructure and increasing funding towards the development of hematology products in this region.